How quickly do physicians adopt new drugs? The case of second-generation antipsychotics

Psychiatric Services

Volumn 64, Issue 4, 2013, Pages 324-330

  Huskamp, Haiden A ^a   O'Malley, A James ^a   Horvitz Lennon, Marcela ^b   Taub, Anna Levine ^c,d   Berndt, Ernst R ^e   Donohue, Julie M ^f  

^a HARVARD MEDICAL SCHOOL   (United States)

^b RAND CORPORATION   (United States)

^c International Arbitration and Litigation Practice   (United States)

^d NORTHEASTERN UNIVERSITY   (United States)

^e MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^f UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; FLUOXETINE PLUS OLANZAPINE; NEW DRUG; OLANZAPINE; PALIPERIDONE; PRESCRIPTION DRUG; QUETIAPINE; RISPERDAL M TAB; RISPERIDONE; UNCLASSIFIED DRUG; ZIPRASIDONE;

ADULT; ARTICLE; CLINICAL EDUCATION; DEMOGRAPHY; DRUG SAFETY; FEMALE; GENERAL PRACTITIONER; HUMAN; MALE; MEDICAL EDUCATION; MEDICAL PRACTICE; MEDICAL SCHOOL; MEDICAL SOCIETY; MENTAL DISEASE; NORMAL HUMAN; PRESCRIPTION; PROPORTIONAL HAZARDS MODEL; SURVIVAL RATE;

ADULT; ANTIPSYCHOTIC AGENTS; DRUG UTILIZATION; FEMALE; GENERAL PRACTICE; GROUP PRACTICE; HUMANS; MALE; MIDDLE AGED; NEUROLOGY; PEDIATRICS; PHYSICIAN'S PRACTICE PATTERNS; PROPORTIONAL HAZARDS MODELS; PSYCHIATRY; RETROSPECTIVE STUDIES; TIME FACTORS; UNITED STATES;

EID: 84883127827     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/appi.ps.201200186     Document Type: Article

References (35)

1. Newhouse JP: Medical care costs: how much welfare loss? Journal of Economic Perspectives 6:3-21, 1992
2. Leucht S, Pitschel-Walz G, Abraham D, et al: Efficacy and extrapyramidal sideeffects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: A meta-analysis of randomized controlled trials. Schizophrenia Research 35:51-68, 1999
3. Correll CU, Leucht S, Kane JM: Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies. American Journal of Psychiatry 161:414-425, 2004
4. Kerwin R, Taylor D: New antipsychotics: A review of their current status and clinical potential. CNS Drugs 6:71-82, 1996
5. Davis JM, Chen N, Glick ID: A metaanalysis of the efficacy of second-generation antipsychotics. Archives of General Psychiatry 60:553-564, 2003
6. Aparasu RR, Bhatara V: Antipsychotic use and expenditure in the United States. Psychiatric Services 57:1693, 2006
7. Lieberman JA, Stroup TS, McEvoy JP, et al: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353:1209-1223, 2005
8. Jones PB, Barnes TR, Davies L, et al: Randomized controlled trial of the effect on quality of life of second-vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Archives of General Psychiatry 63:1079-1087, 2006
9. Carpenter WT, Buchanan RW: Lessons to take home from CATIE. Psychiatric Services 59:523-525, 2008
10. Sharfstein S: Antipsychotics, economics, and the press. Psychiatric News 40:3, 2005
11. Newcomer JW: Second-generation (atypical) antipsychotics and metabolic effects: A comprehensive literature review. CNS Drugs 19(suppl 1):1-93, 2005
12. Meyer JM, Davis VG, Goff DC, et al: Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE schizophrenia trial: prospective data from phase 1. Schizophrenia Research 101:273-286, 2008
13. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists, et al: Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27:596-601, 2004
14. Woods SW, Morgenstern H, Saksa JR, et al: Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: A prospective cohort study. Journal of Clinical Psychiatry 71:463-474, 2010
15. National Collaborating Centre for Mental Health: Schizophrenia: The NICE Guideline on Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care (Updated Edition). London, British Psychological Society and the Royal College of Psychiatrists, 2010. Available at www.nice.org.uk/nicemedia/pdf/CG82FullGuideline.pdf
16. Dixon L, Perkins D, Calmes C: Guideline Watch (September 2009): Practice Guideline for the Treatment of Patients With Schizophrenia. Arlington, Va, American Psychiatric Association, 2009. Available at www.valueoptions.com/ providers/Handbook/treatment/Schizophrenia-Guideline-Watch.pdf
17. Baugh DK, Pine PL, Blackwell S, et al: Medicaid spending and utilization for central nervous system drugs. Health Care Financing Review 26:57-73, 2004
18. Schneeweiss S, Glynn RJ, Avorn J, et al: A Medicare database review found that physician preferences increasingly outweighed patient characteristics as determinants of first-time prescriptions for COX-2 inhibitors. Journal of Clinical Epidemiology 58:98-102, 2005
19. Solomon DH, Schneeweiss S, Glynn RJ, et al: Determinants of selective cyclooxygenase-2 inhibitor prescribing: Are patient or physician characteristics more important? American Journal of Medicine 115:715-720, 2003
20. Hellerstein JK: The importance of the physician in the generic versus trade-name prescription decision. Rand Journal of Economics 29:108-136, 1998
21. Hodgkin D, Volpe-Vartanian J, Merrick EL, et al: Customization in prescribing for bipolar disorder. Health Economics 21: 653-668, 2012
22. Hamann J, Langer B, Leucht S, et al: Medical decision making in antipsychotic drug choice for schizophrenia. American Journal of Psychiatry 161:1301-1304, 2004
23. Steffensen FH, Sørensen HT, Olesen F: Diffusion of new drugs in Danish general practice. Family Practice 16:407-413, 1999
24. AMA Physician Masterfile. Chicago, American Medical Association. Available at www.ama-assn.org/ama/pub/about-ama/physician-data-resources/ physician-masterfile. page
25. Cox DR: Regression models and lifetables. Journal of the Royal Statistical Society 34:187-220, 1972
26. Marder SR, Essock SM, Miller AL, et al: Physical health monitoring of patients with schizophrenia. American Journal of Psychiatry 161:1334-1349, 2004
27. Taub AL, Kolotilin A, Gibbons RS, et al: The Diversity of Concentrated Prescribing Behavior: An Application to Antipsychotics (Working Paper 16823). Cambridge, Mass, National Bureau of Economic Research, 2011
28. Frank RG, Zeckhauser RJ: Custom-made versus ready-to-wear treatments: behavioral propensities in physicians' choices. Journal of Health Economics 26:1101-1127, 2007
29. Greving JP, Denig P, van der Veen WJ, et al: Determinants for the adoption of angiotensin II receptor blockers by general practitioners. Social Science and Medicine 63:2890-2898, 2006
30. Grande D, Frosch DL, Perkins AW, et al: Effect of exposure to small pharmaceutical promotional items on treatment preferences. Archives of Internal Medicine 169: 887-893, 2009
31. Greenhalgh T, Robert G, Macfarlane F, et al: Diffusion of innovations in service organizations: systematic review and recommendations. Milbank Quarterly 82: 581-629, 2004
32. Coleman J, Katz E, Menzel H: The diffusion of an innovation among physicians. Sociometry 20:253-270, 1957
33. Schiff GD, Galanter WL: Promoting more conservative prescribing. JAMA 301:865-867, 2009
34. Gellad WF, Huskamp HA, Li A, et al: Use of prescription drug samples and patient assistance programs, and the role of doctorpatient communication. Journal of General Internal Medicine 26:1458-1464, 2011
35. Soumerai SB: Principles and uses of academic detailing to improve the management of psychiatric disorders. International Journal of Psychiatry in Medicine 28: 81-96, 1998